Akèy › Kansè nan tete › Texas › Houston
Etid klinik pou Kansè nan tete nan Houston, TX
126 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Ap rekriteFaz 3
- Kelsey Seybold Clinic, Houston
- University of Texas, Houston
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Ap rekriteFaz 3
- Research Site, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- UT MD Anderson Cancer Center, Houston
Prediction Of Lymphedema In Patients With Inflammatory BreastCancer Using Preoperative Bioimpedance Measurements
Ap rekriteEtid obsèvasyon
- UT MD Anderson Cancer Center, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Ap rekriteFaz 2
- Texas Oncology Gulf Coast, Houston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Ap rekriteFaz 1/2
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Ap rekriteFaz 1
- Research Site, Houston
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas Md Anderson Cancer Center, Houston
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Ap rekriteFaz 3
- Texas Oncology - Gulf Coast ( Site 8006), Houston
- Oncology Consultants P.A. ( Site 0061), Houston
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas Md Anderson Cancer Center, Houston
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Ap rekrite
- M D Anderson Cancer Center, Houston
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
Ap rekriteFaz 2/3
- M D Anderson Cancer Center, Houston
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- Kelsey-Seybold Clinic ( Site 0042), Houston
- Kelsey-Seybold Clinic ( Site 0088), Houston
- Oncology Consultants P.A. ( Site 0073), Houston
Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer
Ap rekrite
- The University of Texas M. D. Anderson Cancer Center, Houston
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Ap rekriteFaz 2
- Houston Methodist Cancer Center, Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
Ap rekriteFaz 1
- Houston Methodist Hospital, Houston
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Ap rekriteFaz 3
- Clinical Trial Site, Houston
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Ap rekrite
- Houston Methodist Hospital, Houston
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- The University of Texas MD Anderson Cancer Center, Houston
- Houston Methodist Hospital, Houston
- Oncology Consultants P.A., Houston
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
Ap rekrite
- Baylor College of Medicine, Houston
- MD Anderson Cancer Clinic - Mays Clinic, Houston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Ap rekriteFaz 2
- University of Texas MD Anderson Cancer Center, Houston
- Houston Methodist Hospital, Houston
- Oncology Consultants P.A., Houston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Ap rekriteFaz 1
- Baylor College of Medicine, Houston
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Ap rekriteFaz 2
- Baylor College of Medicine, Houston
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Ap rekriteFaz 1
- M D Anderson Cancer Center, Houston
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
Ap rekrite
- Baylor Medicine, Houston
- MD Anderson Cancer Center, Houston
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Ap rekriteFaz 3
- Oncology Consultants PA, Houston
- Oncology Consultants PA, Houston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- Oncology Consultants, P.A., Houston
- The University of Texas MD Anderson Cancer Center, Houston
- Harris Health System - Smith Clinic, Houston
- ak 1 plis
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Ap rekriteFaz 1
- Md Anderson Cancer Center, Houston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Houston
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Ap rekriteFaz 2
- Houston Methodist Hospital ( Site 0022), Houston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Oncology Consultants, Houston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- MD Anderson Cancer Center - University of Texas, Houston
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- UT MD Anderson, Houston
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Ap rekriteFaz 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
Ap rekriteFaz 1
- Oncology Consultants PA, Houston
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas - MD Anderson Cancer Center, Houston
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of Texas-MD Anderson, Houston
- Lumi Research, Houston
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Ap rekriteFaz 3
- Houston Methodist Hospital Cancer Center, Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Ap rekriteEtid obsèvasyon
- UT Health Houston, Houston
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- M. D. Anderson Cancer Center, Houston
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Ap rekriteEtid obsèvasyon
- MD Anderson Cancer Center, Houston
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
Ap rekriteFaz 2
- The University of Texas M. D. Anderson Cancer Center, Houston
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Lyndon Baines Johnson General Hospital, Houston
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- ak 5 plis
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center Uni of Te, Houston
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Ap rekriteFaz 2
- Baylor College of Medicine, Houston
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson, Houston
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Ap rekriteFaz 1
- M D Anderson Cancer Center, Houston
Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)
Ap rekrite
- The University of Texas M. D. Anderson Cancer Center, Houston
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- M D Anderson Cancer Center, Houston
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- (USOR) Texas Oncology, Houston
Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics
Ap rekriteVolontè an sante akeyi
- MD Anderson Cancer Center, Houston
Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue
Ap rekriteEtid obsèvasyon
- MD Anderson Cancer Center, Houston
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Ap rekriteFaz 3
- Baylor College of Medicine - Dan L. Duncan Comprehensive Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Ap rekriteFaz 1
- UT MD Anderson Cancer Center, Houston
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
Ap rekriteVolontè an sante akeyi
- The University of Texas MD Anderson Cancer Center, Houston
A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
Ap rekriteFaz 1
- The University of Texas M. D. Anderson Cancer Center, Houston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Ap rekriteFaz 1
- Uni Of TX MD Anderson Cancer Cntr, Houston
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Ap rekriteFaz 2
- UT MD Anderson Cancer Center, Houston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Ap rekriteFaz 2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- The University of Texas - M.D. Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Ap rekriteFaz 1
- M D Anderson Cancer Center, Houston
The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts
Ap rekrite
- M D Anderson Cancer Center, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of Texas MD Anderson Cancer Center, Houston
Improving Comprehensive Care of Cancer Patients
Ap rekriteVolontè an sante akeyi
- Baylor College of Medicine, Houston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson, Houston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation
Ap rekriteFaz 3
- M D Anderson Cancer Center, Houston
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Ap rekriteFaz 3
- Baylor College of Medicine, Houston
- MD Anderson Cancer Center, Houston
- Harris Health System - Smith Clinic, Houston
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Ap rekriteFaz 2
- Houston Methodist Neal Cancer Center, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
Ap rekrite
- M D Anderson Cancer Center, Houston
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
Ap rekrite
- M D Anderson Cancer Center, Houston
Multi-center MRD Registry for Inflammatory Breast Cancer
Ap rekriteEtid obsèvasyon
- MD Anderson Cancer Center, Houston
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Ap rekriteFaz 3
- University of Texas MD Anderson Cancer Center, Houston
EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial
Ap rekriteFaz 2
- The University of Texas M. D. Anderson Cancer Center, Houston
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Ap rekriteFaz 3
- University of Texas MD Anderson Cancer Center, Houston
- MD Anderson West Houston, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- M D Anderson Cancer Center, Houston
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- Houston Methodist Hospital, Houston
- M D Anderson Cancer Center, Houston
- Methodist Willowbrook Hospital, Houston
- ak 2 plis
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
Ap rekrite
- M D Anderson Cancer Center, Houston
Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer
Ap rekrite
- M D Anderson Cancer Center, Houston
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
- MD Anderson in Katy, Houston
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Ap rekriteFaz 1/2
- Oncology Consultants, Houston
- Next Oncology, Houston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Ap rekriteEtid obsèvasyon
- Md Anderson Cancer Center, Houston
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Ap rekriteFaz 1
- Baylor St. Luke's Medical Center, Houston
Converting HR+ Breast Cancer Into an Individualized Vaccine
Ap rekriteFaz 2
- Houston Methodist Cancer Center, Houston
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Ap rekriteEtid obsèvasyon
- The University of Texas MD Anderson Cancer Center, Houston
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
Ap rekrite
- Baylor St Luke's Medical Centre, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Houston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Ap rekriteFaz 1
- The University of Texas M.D. Anderson Cancer Center, Houston
TRUDI: TDXD+Durva in HER2+/Low IBC
Ap rekriteFaz 2
- University of Texas MD Anderson Cancer Center, Houston
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #1, Houston
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Ap rekriteEtid obsèvasyon
- Texas Oncology - Memorial City, Houston
- Texas Oncology Willowbrook, Houston
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
Ap rekriteFaz 1
- Biotheryx Investigative Site, Houston
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Ap rekriteFaz 2
- Harris Health System - Smith Clinic, Houston
- O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston
BostonGene and Exigent Genomic INsight Study
Ap rekriteEtid obsèvasyon
- Oncology Consultants, Houston
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Ap rekriteEtid obsèvasyon
- The University of Texas MD Anderson Cancer Center, Houston
Comprehensive Outcomes for After Cancer Health
Ap rekriteVolontè an sante akeyi
- The University of Texas MD Anderson Cancer Center, Houston
- UT Health Houston, Houston
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
Ap rekriteFaz 3
- Baylor College Of Medicine, Houston
Etid Kansè nan tete nan lòt vil
- New York City, NY134 etid
- Boston, MA111 etid
- Nashville, TN80 etid
- Los Angeles, CA72 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Durham, NC63 etid
- Queens, NY63 etid
- Chicago, IL58 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
- Baltimore, MD47 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
- Karsinòm selil skuamèz tèt ak kou47 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.